31 May 2022 - Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date.
PTC Therapeutics today announced that the U.S. FDA has approved a label extension for Evrysdi (risdiplam) to include infants under 2 months old with spinal muscular atrophy.